Horizon Reports the New Analysis of Uplizna (inebilizumab-cdon) in the P-III (N-MOmentum) Trial for Neuromyelitis Optica Spectrum Disorder
Shots:
- The 2 P-II POC studies evaluate VX-548 (selective NaV1.8 inhibitor) vs PBO in 274 & 303 patients with acute pain, following abdominoplasty surgery or bunionectomy surge. The study also included HB/APAP (5mg/325mg, PO, q6h over 42hrs.) to support the evaluation of the VX-548 treatment effect
- The trial met its 1EPs in both acute pain studies i.e., improvement in SPID48 at the high dose @48hrs. was well tolerated in both studies, fewer patients discontinued treatment in the mid & high-dose VX-548 or HB/APAP reference arm, no patients discontinued treatment due to AEs & no patients had SAEs
- The company plans to advance VX-548 into pivotal development in H2’22, following discussions with regulators
Ref: Businesswire | Image: Horizon
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
